Bio-Pharm Solutions Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 19, 2026The maintenance fee for Phenyl carbamate compounds for use in preventing or treating stroke (US 9,034,848) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
- 1 fee due Jan 16, 2027The maintenance fee for Sulfamate derivative compounds, processes for preparing them and their uses (US 10,351,519) comes due Jan 16, 2027. Unpaid by Jul 16, 2027, it lapses early.
- 2 fees due Apr 20 to 24, 2027 · next Apr 20
- 1 fee due Jun 29, 2027The maintenance fee for Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same (US 9,221,783) comes due Jun 29, 2027. Unpaid by Dec 29, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Phenyl carbamate compound and a composition for neuroprotection comprising the same (US 10,525,030) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 1 fee due Aug 13, 2027The maintenance fee for Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder (US 11,896,593) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
- 1 fee due Sep 19, 2027The maintenance fee for Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease (US 11,931,332) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,018,253 | Phenylcarbamate compound and muscle relaxant containing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 8,859,817 | Process for preparation of phenyl carbamate derivatives In force · From the USPTO record | In force | From the USPTO record | |
| US 9,624,164 | Phenyl carbamate compounds for use in preventing or treating epilepsy In force · From the USPTO record | In force | From the USPTO record | |
| US 9,162,975 | Phenyl carbamate compounds for use in alleviating or treating pain In force · From the USPTO record | In force | From the USPTO record | |
| US 9,029,589 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,221,783 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,034,848 | Phenyl carbamate compounds for use in preventing or treating stroke In force · From the USPTO record | In force | From the USPTO record | |
| US 9,504,668 | Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome In force · From the USPTO record | In force | From the USPTO record | |
| US 9,682,059 | Phenyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome In force · From the USPTO record | In force | From the USPTO record | |
| US 9,872,847 | Phenyl carbamate compounds for use in preventing or treating a movement disorder In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 23: 4 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 no status recorded